Sebastian Lunemann1, Gloria Martrus1, Angelique Hölzemer2, Anais Chapel1, Maja Ziegler1, Christian Körner1, Wilfredo Garcia Beltran3, Mary Carrington4, Heiner Wedemeyer5, Marcus Altfeld6. 1. Department for Viral Immunology, Heinrich-Pette-Institute, Hamburg, Germany. 2. Department of Internal Medicine, University Hospital Eppendorf, Hamburg, Germany. 3. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA. 4. Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, USA; Cancer and Inflammation Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA. 5. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany. 6. Department for Viral Immunology, Heinrich-Pette-Institute, Hamburg, Germany. Electronic address: marcus.altfeld@hpi.uni-hamburg.de.
Abstract
BACKGROUND & AIMS: Both natural killer (NK) cells and human leukocyte antigen (HLA)/killer cell immunoglobulin like receptor (KIR) interactions have been shown to play an important role in the control, clearance and progression of hepatitis C virus (HCV) disease. Here we aimed at elucidating the effects of viral peptides derived from HCV on HLA stabilization, changes in KIR binding and primary NK cell function. METHODS: Transporter for antigen presentation-deficient 722.221 cells stably transfected with HLA-C∗03:04 were used to screen 200 overlapping peptides, covering the non-structural protein 3 (NS3) and core protein of HCV genotype 1, for their ability to bind and stabilize HLA-C∗03:04. Binding of KIR2DL3 to the HLA-peptide complex was assessed using a KIR2DL3-IgG fusion construct. Primary NK cells were isolated from healthy donors to investigate the effects of identified peptides on KIR2DL3(+) NK cell function. RESULTS: Thirty-one peptides able to stabilize HLA-C∗03:04 were identified. One 9mer peptide, YIPLVGAPL, resulted in significantly higher KIR2DL3 binding to HLA-C∗03:04(+) 722.221 cells and suppression of primary KIR2DL3(+) NK cell function. Interestingly this sequence exhibited a high frequency of mutations in different HCV genotypes. These genotype-specific peptides showed lower HLA-C∗03:04 stabilization, decreased binding of the inhibitory KIR2DL3 and lower inhibition of NK cell function. CONCLUSIONS: Taken together we show that a viral peptide derived from the core protein of HCV genotype 1 binding to HLA-C∗03:04 results in a sequence-dependent engagement of the inhibitory NK cell receptor KIR2DL3, while the large majority of the remaining 30 HLA-C∗03:04 binding HCV core peptides did not. These data show that sequence variations within HCV can modulate NK cell function, providing potential pathways for viral escape. LAY SUMMARY: We identified a HCV peptide that dampens NK cell responses, and thereby possibly prevents killing of infected cells through this part of the innate immune system. This is facilitated via presentation of the viral peptide on HLA∗03:04 to the inhibitory KIR receptor KIR2DL3 on NK cells. Naturally occurring sequence mutations in the peptide alter these interactions making the inhibition less efficient.
BACKGROUND & AIMS: Both natural killer (NK) cells and human leukocyte antigen (HLA)/killer cell immunoglobulin like receptor (KIR) interactions have been shown to play an important role in the control, clearance and progression of hepatitis C virus (HCV) disease. Here we aimed at elucidating the effects of viral peptides derived from HCV on HLA stabilization, changes in KIR binding and primary NK cell function. METHODS: Transporter for antigen presentation-deficient 722.221 cells stably transfected with HLA-C∗03:04 were used to screen 200 overlapping peptides, covering the non-structural protein 3 (NS3) and core protein of HCV genotype 1, for their ability to bind and stabilize HLA-C∗03:04. Binding of KIR2DL3 to the HLA-peptide complex was assessed using a KIR2DL3-IgG fusion construct. Primary NK cells were isolated from healthy donors to investigate the effects of identified peptides on KIR2DL3(+) NK cell function. RESULTS: Thirty-one peptides able to stabilize HLA-C∗03:04 were identified. One 9mer peptide, YIPLVGAPL, resulted in significantly higher KIR2DL3 binding to HLA-C∗03:04(+) 722.221 cells and suppression of primary KIR2DL3(+) NK cell function. Interestingly this sequence exhibited a high frequency of mutations in different HCV genotypes. These genotype-specific peptides showed lower HLA-C∗03:04 stabilization, decreased binding of the inhibitory KIR2DL3 and lower inhibition of NK cell function. CONCLUSIONS: Taken together we show that a viral peptide derived from the core protein of HCV genotype 1 binding to HLA-C∗03:04 results in a sequence-dependent engagement of the inhibitory NK cell receptor KIR2DL3, while the large majority of the remaining 30 HLA-C∗03:04 binding HCV core peptides did not. These data show that sequence variations within HCV can modulate NK cell function, providing potential pathways for viral escape. LAY SUMMARY: We identified a HCV peptide that dampens NK cell responses, and thereby possibly prevents killing of infected cells through this part of the innate immune system. This is facilitated via presentation of the viral peptide on HLA∗03:04 to the inhibitory KIR receptor KIR2DL3 on NK cells. Naturally occurring sequence mutations in the peptide alter these interactions making the inhibition less efficient.
Authors: Salim I Khakoo; Chloe L Thio; Maureen P Martin; Collin R Brooks; Xiaojiang Gao; Jacquie Astemborski; Jie Cheng; James J Goedert; David Vlahov; Margaret Hilgartner; Steven Cox; Ann-Margeret Little; Graeme J Alexander; Matthew E Cramp; Stephen J O'Brien; William M C Rosenberg; David L Thomas; Mary Carrington Journal: Science Date: 2004-08-06 Impact factor: 47.728
Authors: Stefan Zeuzem; Tarik Asselah; Peter Angus; Jean-Pierre Zarski; Dominique Larrey; Beat Müllhaupt; Ed Gane; Marcus Schuchmann; Ansgar W Lohse; Stanislas Pol; Jean-Pierre Bronowicki; Stuart Roberts; Keikawus Arasteh; Fabien Zoulim; Markus Heim; Jerry O Stern; Gerhard Nehmiz; George Kukolj; Wulf O Böcher; Federico J Mensa Journal: Antivir Ther Date: 2013-04-04
Authors: Lena Fadda; Christian Körner; Swati Kumar; Nienke H van Teijlingen; Alicja Piechocka-Trocha; Mary Carrington; Marcus Altfeld Journal: PLoS Pathog Date: 2012-07-12 Impact factor: 6.823
Authors: Jane P Messina; Isla Humphreys; Abraham Flaxman; Anthony Brown; Graham S Cooke; Oliver G Pybus; Eleanor Barnes Journal: Hepatology Date: 2014-07-28 Impact factor: 17.425
Authors: A B Hill; S P Lee; J S Haurum; N Murray; Q Y Yao; M Rowe; N Signoret; A B Rickinson; A J McMichael Journal: J Exp Med Date: 1995-06-01 Impact factor: 14.307
Authors: Thomas van Stigt Thans; Janet I Akko; Annika Niehrs; Wilfredo F Garcia-Beltran; Laura Richert; Christina M Stürzel; Christopher T Ford; Hui Li; Christina Ochsenbauer; John C Kappes; Beatrice H Hahn; Frank Kirchhoff; Glòria Martrus; Daniel Sauter; Marcus Altfeld; Angelique Hölzemer Journal: J Virol Date: 2019-09-30 Impact factor: 5.103
Authors: David F G Malone; Sebastian Lunemann; Julia Hengst; Hans-Gustaf Ljunggren; Michael P Manns; Johan K Sandberg; Markus Cornberg; Heiner Wedemeyer; Niklas K Björkström Journal: Front Immunol Date: 2017-05-08 Impact factor: 7.561
Authors: Malcolm J W Sim; Stacy A Malaker; Ayesha Khan; Janet M Stowell; Jeffrey Shabanowitz; Mary E Peterson; Sumati Rajagopalan; Donald F Hunt; Daniel M Altmann; Eric O Long; Rosemary J Boyton Journal: Front Immunol Date: 2017-03-14 Impact factor: 7.561
Authors: Maja Christiane Ziegler; Ferran Borràs Grañana; Wilfredo F Garcia-Beltran; Julian Schulze Zur Wiesch; Christian Hoffmann; Anne Rechtien; Sebastian Lunemann; Marcus Altfeld Journal: Front Immunol Date: 2018-10-17 Impact factor: 7.561